Avantax Planning Partners, Inc. Gilead Sciences, Inc. Transaction History
Avantax Planning Partners, Inc.
- $3.45 Billion
- Q3 2025
A detailed history of Avantax Planning Partners, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Avantax Planning Partners, Inc. holds 3,303 shares of GILD stock, worth $409,869. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,303
Previous 3,676
10.15%
Holding current value
$409,869
Previous $407,000
10.07%
% of portfolio
0.01%
Previous 0.01%
Shares
32 transactions
Others Institutions Holding GILD
# of Institutions
2,408Shares Held
1.01BCall Options Held
8.51MPut Options Held
7.32M-
Vanguard Group Inc Valley Forge, PA121MShares$15 Billion0.23% of portfolio
-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $156B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...